Market Place
Sourcing Support
Volition Inks First Human Out Licensing Agreement
09 Sep 2025 //
PR NEWSWIRE
Volition Rx Reports Q2 2025 Financials and Business Update
14 Aug 2025 //
PR NEWSWIRE
Nu.Q® Discover Boosts Global Adoption, Epigenetic Innovation
16 Jul 2025 //
PR NEWSWIRE
Volition Study Shows Nu.Q® H3.1. Linked to Sepsis
12 Jun 2025 //
PR NEWSWIRE
Volition presents two posters at ESMO Lung Cancer Congress 2025
28 Mar 2025 //
PR NEWSWIRE
VolitionRx Prices $2.3M Direct Offering
26 Mar 2025 //
PR NEWSWIRE
Volition Signs First Project Using High-Throughput NETosis Model
06 Feb 2025 //
PR NEWSWIRE
Volition appoints Dr Andrew Retter as Chief Medical Officer
19 Mar 2024 //
PR NEWSWIRE
VolitionRx Announces Pricing of $16.5M Underwritten Public Offering of Stock
01 Jun 2023 //
PR NEWSWIRE
Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test
20 Oct 2022 //
PRNEWSWIRE
Volition Announces U.S. Clinical Study for NETs
10 Aug 2022 //
PR NEWSWIRE
Volition appoints Sharon Ballesteros as Head of Quality, Development Process
06 Apr 2022 //
PRNEWSWIRE
VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results
30 Mar 2022 //
PRNEWSWIRE
Volition Executes Supply & Licensing Contract for Nu.Q Vet Cancer Screening Test
16 Dec 2021 //
PRNEWSWIRE
VolitionRx Limited to Webcast Live at Life Sciences Investor Forum June 24th
21 Jun 2021 //
GLOBENEWSWIRE
VolitionRx Limited to Present at Conferences in March 2021
09 Mar 2021 //
PRNASIA
VolitionRx Announces Closing of $20 M Underwritten Public Offering
12 Feb 2021 //
PRNASIA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.